title: Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
abstract: Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents.
authors.affiliation: CERIA (Centre for Research on Angiogenesis Inhibitors), Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Tlemsani
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
authors.forename: Pascaline
authors.initials: P
authors.lastname: Boudou-Rouquette
authors.forename: Olivier
authors.initials: O
authors.lastname: Huillard
authors.forename: Karin
authors.initials: K
authors.lastname: Maley
authors.forename: Stanislas
authors.initials: S
authors.lastname: Ropert
authors.forename: Romain
authors.initials: R
authors.lastname: Coriat
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A
references.citation: Ann Oncol. 2007 Oct;18(10):1745-7
references.pmid: 17890216
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1432-9
references.pmid: 19224847
references.citation: J Clin Oncol. 2011 Oct 1;29(28):e739-42
references.pmid: 21900098
references.citation: Ann Oncol. 2009 May;20(5):807-15
references.pmid: 19150949
references.citation: QJM. 2012 Jan;105(1):69-75
references.pmid: 21865314
references.citation: J Neurol. 2008 Feb;255(2):295-6
references.pmid: 18283405
references.citation: J Clin Endocrinol Metab. 2003 Nov;88(11):5555-63
references.pmid: 14602804
references.citation: Hong Kong Med J. 2011 Feb;17(1):80-1
references.pmid: 21282833
references.citation: J Clin Oncol. 2006 Oct 1;24(28):e48
references.pmid: 17008686
references.citation: N Engl J Med. 1996 Feb 22;334(8):494-500
references.pmid: 8559202
references.citation: Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):605-7
references.pmid: 18565360
references.citation: Ann Oncol. 2007 Oct;18(10):1747-50
references.pmid: 17890217
references.citation: Br J Clin Pharmacol. 2008 May;65(5):793-4
references.pmid: 18279475
references.citation: Arch Neurol. 2008 Feb;65(2):175-6
references.pmid: 18268184
references.citation: Dis Colon Rectum. 2008 Sep;51(9):1425-6
references.pmid: 18470563
references.citation: J Ocul Pharmacol Ther. 2010 Jun;26(3):301-3
references.pmid: 20565319
references.citation: Semin Neurol. 2011 Apr;31(2):202-15
references.pmid: 21590625
references.citation: Ann Oncol. 2009 May;20(5):967-70
references.pmid: 19403940
references.citation: Med Oncol. 2010 Dec;27(4):1436-7
references.pmid: 20012235
references.citation: Mayo Clin Proc. 2011 Sep;86(9):851-6
references.pmid: 21878596
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5320-1
references.pmid: 18024878
references.citation: J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
references.pmid: 17686822
references.citation: Intern Med J. 2009 May;39(5):341-2
references.pmid: 19382984
references.citation: Br J Clin Pharmacol. 2011 May;71(5):777-9
references.pmid: 21480952
references.citation: N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2
references.pmid: 16510760
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3559
references.pmid: 17687168
references.citation: J Natl Cancer Inst. 2008 Feb 20;100(4):282-4
references.pmid: 18270341
references.citation: Clin Exp Ophthalmol. 2008 Jan-Feb;36(1):94-6
references.pmid: 18290962
references.citation: N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2
references.pmid: 16514715
references.citation: EMBO J. 1989 Dec 1;8(12):3801-6
references.pmid: 2684646
references.citation: J Thorac Oncol. 2010 Jul;5(7):1054-9
references.pmid: 20593550
references.citation: Clin Cancer Res. 2009 Oct 1;15(19):6277-83
references.pmid: 19773375
references.citation: J Gastrointest Cancer. 2012 Sep;43(3):505-7
references.pmid: 21556724